Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
SKOKIE, Ill., Feb. 12, 2016 -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David Prize in the Future Time Dimension. Dr. Mirkin is being awarded the prize for his ground-breaking contributions to the field of nanoscience. His work led to the invention of 3-D structures called spherical nucleic acids (SNAs) which are currently being developed by Exicure. The prize will be presented on Sunday, May 22, 2016, at Tel Aviv University in Tel Aviv, Israel.
“The Dan David Prize recognizing Chad Mirkin’s work is continued validation of the SNA technology’s great potential to fulfill the promise of nucleic acid therapeutics in organs beyond the liver,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “This is another high honor for Chad and for our SNA platform.”
The international Dan David Prize is awarded annually for outstanding contributions to humanity in three time dimensions: past, present, and future. This year, the future time dimension prize recognizes proven, exceptional, and distinct excellence in the field of nanoscience.
About Spherical Nucleic Acids
SNAs are nanoscale, spherical arrangements of densely packed and radially oriented nucleic acids. This architecture overcomes one of the most difficult obstacles to nucleic acid based therapeutics: safe and effective delivery into cells and tissues of therapeutic importance without the need for additional physical or chemical methods or components. The SNAs can be designed to be extremely potent and highly targeted gene regulation and immune-modulatory agents.
About Exicure
Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene-silencing drugs against validated targets. Our 3-D, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
Media Contact: Karen Sharma MacDougall Biomedical Communications 781-235-3060 [email protected]
